Evinacumab, a monoclonal antibody inhibiting ANGPTL3, is an effective and safe lipid-lowering therapy for patients with homozygous and heterozygous familial hypercholesterolemia.
Does evinacumab improve lipid profiles in patients with familial hypercholesterolemia and resistant dyslipidemia?
This review highlights evinacumab as an effective and safe therapeutic strategy for reducing LDL-C and triglycerides in patients with severe and resistant forms of dyslipidemia.
Familial hypercholesterolemia (FH) is an inherited disorder. The level of low-density lipoprotein cholesterol (LDL-C) in patients with homozygous FH can be twice as high as that in patients with heterozygous FH. The inhibition of ANGPTL3 shows an important therapeutic approach in reducing LDL-C and triglycerides (TG) levels and, thus, is a potentially effective strategy in the treatment of FH. Evinacumab is a monoclonal antibody inhibiting circulating ANGPTL3, available under the trade name Evkeeza® for the treatment of homozygous FH. It was reported that evinacumab is effective and safe in patients with homozygous and heterozygous FH, as well as resistant hypercholesterolemia and hypertriglyceridemia. This paper summarizes existing knowledge on the role of ANGPTL3, 4, and 8 proteins in lipoprotein metabolism, the findings from clinical trials with evinacumab, a fully human ANGPTL3 mAb, and the place for this new agent in lipid-lowering therapy.
Sosnowska et al. (Sun,) conducted a review in Dyslipidemia and Familial hypercholesterolemia. Evinacumab was evaluated. Evinacumab, a monoclonal antibody inhibiting ANGPTL3, is an effective and safe lipid-lowering therapy for patients with homozygous and heterozygous familial hypercholesterolemia.